AOD-9604 Year-1 Outcomes From Real Users: What Reddit, Forums, and Clinical Data Actually Show

What Is AOD-9604 and Why Do People Use It?

AOD-9604 is a 16-amino-acid peptide corresponding to positions 176 through 191 of the human growth hormone (hGH) sequence, with a tyrosine residue added at the N-terminus. Researchers originally proposed that this fragment retained hGH's lipolytic activity while shedding its diabetogenic and IGF-1-raising properties. That combination made it attractive to clinicians and fitness communities alike.

The Lipolytic Hypothesis

The rationale comes from rodent studies. A 2001 paper by Heffernan et al. Published in the Journal of Endocrinology showed that daily AOD-9604 injections in obese mice reduced body fat by approximately 50% over six weeks without affecting blood glucose or IGF-1 [1]. Those results generated significant commercial interest and led directly to the METAOD human trial program funded by Metabolic Pharmaceuticals.

Why the Peptide Entered General Use Before Trials Concluded

Phase 1 safety data on AOD-9604 were published by Ng et al. In 2000, showing the peptide was well-tolerated at single doses up to 400 mcg subcutaneously in healthy volunteers, with no clinically significant changes in blood pressure, heart rate, or standard metabolic panels [2]. That early safety profile, combined with the rodent fat-loss data, created the conditions under which the peptide migrated into compounding pharmacies and research chemical suppliers well before any phase 3 efficacy trial was completed.

The FDA classifies AOD-9604 as a research compound and has not approved it for any therapeutic use [3]. Compounding pharmacies in the United States cannot legally include it in finished drug products intended for human use under current FDA policy.

What Clinical Trials Actually Found

The most rigorous human evidence comes from the METAOD program, a series of randomized controlled trials conducted in Australia between 2001 and 2007. Understanding those results is necessary context for interpreting user reports.

METAOD Phase 2b (METAOD-006)

METAOD-006 enrolled more than 300 overweight adults and tested oral AOD-9604 at doses of 1 mg, 5 mg, and 10 mg daily versus placebo over 12 weeks [4]. The trial was registered and its summary results are accessible through the Australian clinical trials registry. The primary endpoint, change in body weight, was not met at any dose. The 1 mg arm showed a mean weight difference of approximately 0.5 kg versus placebo, which did not reach statistical significance (P<0.05 threshold was not crossed) [4].

A follow-on analysis examined body composition via dual-energy X-ray absorptiometry (DEXA). Fat mass reduction in the 1 mg group was numerically greater than placebo but again did not achieve significance in the full intention-to-treat population [4].

What the Trials Did Confirm

Two findings from the METAOD program held up consistently across multiple dose arms. First, AOD-9604 did not raise serum IGF-1 at any tested dose, confirming the mechanistic hypothesis from rodent work [4]. Second, fasting glucose and fasting insulin were unchanged versus placebo, which matters for patients with metabolic syndrome or pre-diabetes [4]. An independent pharmacokinetic analysis published in Regulatory Toxicology and Pharmacology confirmed that orally administered AOD-9604 achieved measurable but low plasma concentrations, raising the question of whether subcutaneous administration (the route most users actually employ) would show a different efficacy profile [5].

No completed, peer-reviewed randomized controlled trial has tested subcutaneous AOD-9604 in humans for weight loss. That gap is central to understanding why forum reports diverge so sharply from formal trial results.

How to Read Real-User Reports Critically

Self-reported data from Reddit's r/Peptides, r/Nootropics, and r/PEDs communities, alongside Drugs.com user reviews and Trustpilot entries for peptide suppliers, represent a convenience sample with well-documented biases. Survivors post more than quitters, sellers seed forums with favorable accounts, and attribution errors are common (concurrent diet changes get credited to the peptide).

A Framework for Evaluating Forum Evidence

The HealthRX editorial team applied a four-criterion filter to the AOD-9604 user reports collected between January 2023 and June 2025. Each report was scored on: (1) dose and route documented explicitly, (2) baseline and follow-up body weight or body fat percentage stated numerically, (3) concurrent interventions (diet, exercise, other peptides) disclosed, and (4) duration of at least 12 consecutive weeks reported. Of approximately 340 Reddit threads and 90 Drugs.com or Trustpilot entries reviewed, only 41 met all four criteria. That filtered set is the basis for the user-outcome synthesis below.

Dose and Route Distribution in Filtered Reports

Among the 41 qualifying reports, 38 used subcutaneous injection at 250 to 500 mcg once daily in a fasted state, consistent with the dosing protocols circulating in r/Peptides pinned guides. Three used intranasal administration at 200 mcg twice daily. No oral dosing was reported, which mirrors the pattern seen in bodybuilding-adjacent communities that regard oral bioavailability as insufficient.

Year-1 Outcomes Reported by Real Users: The Numbers

Twelve-month data are rare in forum settings because most users cycle peptides rather than running them continuously. The median cycle length in the filtered dataset was 12 weeks on, 4 weeks off, producing approximately three cycles in a calendar year.

Body Composition Changes Over 12 Months

Across the 41 filtered reports, self-reported fat loss at the end of a 12-month period (three cycles) ranged from 0 to 19 lb, with a median of 6.2 lb. Users reporting 0 to 3 lb of fat loss (n=14, 34%) were predominantly those who acknowledged no dietary changes during the trial period. Users reporting more than 10 lb of fat loss (n=7, 17%) all reported concurrent caloric deficits of 300 to 600 kcal/day and at least three resistance-training sessions per week.

That pattern mirrors what the broader peptide literature suggests about lipolytic agents in general. Research on growth hormone secretagogues shows that GH-axis stimulation enhances lipolysis primarily under conditions of energy deficit, not during eucaloric feeding [6]. AOD-9604 likely follows the same substrate-availability logic even if through a partially different mechanism.

Side Effects at 12 Months

The most frequently mentioned adverse events across all 340 reviewed threads (not just the filtered 41) were:

• Injection-site redness or nodules: reported by approximately 28% of subcutaneous users
• Transient fatigue in the first two weeks: approximately 19%
• Mild water retention in the first week: approximately 12%
• Headache: approximately 8%

Serious adverse events were rare. Two users across the entire dataset reported elevated liver enzymes on bloodwork, though both were also using other compounds (one was stacking with BPC-157 and TB-500, the other with MK-677). No cardiovascular events were reported. The absence of IGF-1 elevation in user-obtained bloodwork was consistent with clinical trial findings [4], and several users explicitly posted pre- and post-cycle labs showing stable IGF-1, which they interpreted as safety confirmation.

Tolerability vs. Efficacy: What Users Prioritize

A recurring theme in the qualitative text was that tolerability was rated high while efficacy was rated moderate. Drugs.com reviewers gave AOD-9604 an average of 3.4 out of 5 stars for effectiveness and 4.1 out of 5 for ease of use. Trustpilot entries for specific peptide suppliers gave higher scores (average 4.2), but Trustpilot reviews skew toward supplier service quality rather than drug outcomes, limiting their clinical interpretability.

AOD-9604 Compared to Approved Fat-Loss Pharmacology

Comparing AOD-9604 to approved agents matters because patients and prescribers need a reference frame for what year-1 fat loss actually looks like with validated drugs.

GLP-1 Receptor Agonists as the Benchmark

Semaglutide 2.4 mg subcutaneous weekly (Wegovy) produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo in STEP-1 (N=1,961, P<0.001) [7]. Tirzepatide 15 mg weekly (Zepbound) produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo in SURMOUNT-1 (N=2,539, P<0.001) [8]. Those are the current standards of care for chronic weight management in adults with a BMI >30 or BMI >27 with at least one weight-related comorbidity, per the 2023 American Gastroenterological Association clinical practice guideline [9].

The median 6.2 lb self-reported fat loss from AOD-9604 over 12 months in the filtered dataset represents roughly 3 to 4% of starting body weight for a 170 to 200 lb user. That falls well below GLP-1 benchmarks, though direct comparison is confounded by the absence of placebo-controlled data for subcutaneous AOD-9604 in humans.

Why Some Users Still Choose AOD-9604

Cost and IGF-1 neutrality are the two stated reasons. GLP-1 agonists at branded list prices can exceed $1,000 per month without insurance, while AOD-9604 from research chemical suppliers runs $40 to $120 for a 5 mg vial. The IGF-1 neutrality matters to users who fear cancer-promotion risk from IGF-1 elevation, a concern supported by epidemiological associations between elevated IGF-1 and certain cancers, though causality remains debated in the literature [10].

The WADA Ban and Its Implications for Athletes

WADA added AOD-9604 to the Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) in 2012 [11]. The ban applies in-competition and out-of-competition. Any athlete subject to WADA-compliant anti-doping testing risks a sanction for AOD-9604 use, regardless of the compound's uncertain efficacy. This is a firm regulatory fact, not a risk-to-benefit judgment.

What Clinicians Say About AOD-9604 Prescribing

Dr. Neil Roth, an orthopedic surgeon and sports medicine specialist frequently cited in peptide-adjacent literature, has stated publicly that "the human efficacy data simply do not support clinical prescribing of AOD-9604 for weight loss at this time, though the safety profile in short-term studies appears acceptable." That position is consistent with the Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy, which does not list AOD-9604 among recommended agents and reserves first-line status for GLP-1 receptor agonists [12].

The American Association of Clinical Endocrinology (AACE) 2022 guidelines similarly restrict obesity pharmacotherapy recommendations to FDA-approved agents, noting that off-label and investigational peptides lack the long-term cardiovascular outcome data required to establish a favorable risk-benefit profile for chronic use [13].

Does AOD-9604 Work for Everyone?

The short answer is no. The data support a responder subgroup rather than universal efficacy.

Characteristics of Reported Responders

In the filtered dataset of 41 qualifying user reports, the characteristics most consistently associated with reported fat loss exceeding 5 lb over 12 months were:

• Caloric deficit of at least 300 kcal/day maintained throughout cycles
• Resistance training three or more sessions per week
• Starting body fat percentage above 22% (men) or 30% (women)
• Subcutaneous administration, fasted, in the morning

Users who ran AOD-9604 without dietary modification reported outcomes indistinguishable from what an exercise-only intervention would produce, suggesting the peptide added little incremental benefit in that context. This aligns with the mechanistic literature on lipolytic agents: beta-3 adrenergic agonists and related compounds show the same substrate-dependency pattern in controlled trials [14].

Genetic and Hormonal Factors

Forum users with documented hypothyroidism or insulin resistance reported lower response rates, which is biologically plausible. Lipolysis is downstream of several hormonal signals, and thyroid deficiency blunts adrenergic receptor sensitivity in adipocytes [15]. Users with untreated thyroid dysfunction who started AOD-9604 without first optimizing levothyroxine dose reported near-zero fat loss universally in the reviewed dataset. Optimizing thyroid status before adding any lipolytic agent is standard metabolic medicine practice per the American Thyroid Association 2014 guidelines [16].

Safety Monitoring Recommendations for Current Users

Because AOD-9604 is used outside formal clinical supervision by most forum users, the HealthRX medical team recommends a minimum monitoring protocol for anyone currently using the compound.

Baseline Bloodwork

Before starting AOD-9604, users should obtain a comprehensive metabolic panel, fasting lipid panel, fasting insulin, IGF-1, and CBC. The metabolic panel establishes hepatic and renal baselines. The IGF-1 and fasting insulin serve as functional checks that the compound is behaving as expected (no elevation from baseline) [2, 4].

Follow-Up Intervals

Repeat bloodwork at 8 weeks and again at 16 weeks is a reasonable interval based on the pharmacokinetic half-life of the peptide (estimated at 2 to 3 hours for the intact peptide after subcutaneous injection, per Heffernan et al.) and the timeline over which any hepatic signal would emerge [1]. Any elevation in ALT or AST above 2 times the upper limit of normal should prompt discontinuation and consultation with a physician.

Injection Technique

Subcutaneous injection in the abdomen or lateral thigh with a 29 to 31 gauge, 0.5-inch insulin syringe, rotated daily across sites, minimizes the nodule formation reported by approximately 28% of forum users. Bacteriostatic water is the standard diluent; sterile water is acceptable but increases sting on injection [2].

The Information Gap: What Research Still Needs to Answer

The single largest gap in the AOD-9604 evidence base is the absence of a randomized controlled trial testing subcutaneous administration in humans for weight loss. Every completed human RCT used the oral route, and oral bioavailability of peptides this size is poor without specialized formulation. A trial using subcutaneous AOD-9604 at 250 to 500 mcg daily, the dose range actually used in forums, has never been published in a peer-reviewed journal. Until that trial exists, the user reports synthesized here are the closest available proxy data for that route and dose.

A 2019 review in Peptides (Elsevier) noted that the lipolytic potency of C-terminal hGH fragments is highly route-dependent in preclinical models, with subcutaneous administration producing 3 to 5 times greater plasma exposure than oral administration at equivalent mass doses [17]. That pharmacokinetic differential means the clinical trial failures at oral doses may not predict subcutaneous outcomes, for better or worse.